| Lack of drug-drug interaction between cerivastatin and nifedipine. | |
| | |
MedLine Citation:
|
PMID: 9726692 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cerivastatin is a novel, potent HMG-CoA reductase inhibitor. It is primarily cleared via demethylation and hydroxylation with involvement of cytochrome P450 (CYP) 3A4 and subsequent biliary and renal excretion of the metabolites. Both cerivastatin and the dihydropyridine calcium antagonist nifedipine, which is primarily metabolized by CYP 3A4, are used concomitantly in the prevention and therapy of coronary heart disease. To study the drug-drug interaction potential, the mutual effects of cerivastatin and nifedipine were investigated in a controlled, randomized, non-blind 3-way crossover study in healthy male subjects. Single oral doses of 0.3 mg cerivastatin or of 60 mg nifedipine were administered either alone or concomitantly under fasting conditions. The mean AUC- and Cmax ratios (combination treatment versus monotherapy) including 90% confidence intervals were 1.04 (0.98 - 1.10) and 1.00 (0.93 - 1.07) for cerivastatin, and 0.98 (0.73 - 1.32) and 0.95 (0.80 - 1. 13) for nifedipine, respectively. Our results indicate that no mutual drug-drug interaction between cerivastatin and nifedipine occurs. |
| | |
Authors:
|
R Sachse; E Brendel; W Mück; G Rohde; K Ochmann; R Horstmann; J Kuhlmann |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: International journal of clinical pharmacology and therapeutics Volume: 36 ISSN: 0946-1965 ISO Abbreviation: Int J Clin Pharmacol Ther Publication Date: 1998 Aug |
Date Detail:
|
Created Date: 1998-11-20 Completed Date: 1998-11-20 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9423309 Medline TA: Int J Clin Pharmacol Ther Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 409-13 Citation Subset: IM |
Affiliation:
|
Institute of Clinical Pharmacology, Bayer AG, Wuppertal/Cologne, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Area Under Curve Biological Availability Calcium Channel Blockers / pharmacokinetics* Cross-Over Studies Drug Interactions Half-Life Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics* Male Nifedipine / pharmacokinetics* Pyridines / pharmacokinetics* |
| Chemical | |
Reg. No./Substance:
|
0/Calcium Channel Blockers; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyridines; 0/cerivastatin; 21829-25-4/Nifedipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cytotoxic and genotoxic effects of paclitaxel (Taxol) and radiation in a squamous cell carcinoma cel...
Next Document: Pharmacokinetics of dexibuprofen administered as 200 mg and 400 mg film-coated tablets in healthy vo...